Research output per year
Research output per year
Fingerprint
Dive into the research topics where Montaser Shaheen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
Weiss, S. A., Sznol, M., Shaheen, M., Berciano-Guerrero, M. Á., Couselo, E. M., Rodríguez-Abreu, D., Boni, V., Schuchter, L. M., Gonzalez-Cao, M., Arance, A., Wei, W., Ganti, A. K., Hauke, R. J., Berrocal, A., Iannotti, N. O., Hsu, F. J. & Kluger, H. M., Jan 10 2024, In: Clinical Cancer Research. 30, 1, p. 74-81 8 p.Research output: Contribution to journal › Article › peer-review
Open Access8 Scopus citations -
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
Weber, J. S., Carlino, M. S., Khattak, A., Meniawy, T., Ansstas, G., Taylor, M. H., Kim, K. B., McKean, M., Long, G. V., Sullivan, R. J., Faries, M., Tran, T. T., Cowey, C. L., Pecora, A., Shaheen, M., Segar, J., Medina, T., Atkinson, V., Gibney, G. T. & Luke, J. J. & 14 others, , Feb 17 2024, In: The Lancet. 403, 10427, p. 632-644 13 p.Research output: Contribution to journal › Article › peer-review
59 Scopus citations -
Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial
Adams, A. M., Carpenter, E. L., Clifton, G. T., Vreeland, T. J., Chick, R. C., O’Shea, A. E., McCarthy, P. M., Kemp Bohan, P. M., Hickerson, A. T., Valdera, F. A., Tiwari, A., Hale, D. F., Hyngstrom, J. R., Berger, A. C., Jakub, J. W., Sussman, J. J., Shaheen, M. F., Yu, X., Wagner, T. E. & Faries, M. B. & 1 others, , Mar 2023, In: Cancer Immunology, Immunotherapy. 72, 3, p. 697-705 9 p.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Patel, S. P., Othus, M., Chen, Y., Wright, G. P., Yost, K. J., Hyngstrom, J. R., Hu-Lieskovan, S., Lao, C. D., Fecher, L. A., Truong, T. G., Eisenstein, J. L., Chandra, S., Sosman, J. A., Kendra, K. L., Wu, R. C., Devoe, C. E., Deutsch, G. B., Hegde, A., Khalil, M. & Mangla, A. & 33 others, , 2023, In: New England Journal of Medicine. 388, 9, p. 813-823 11 p.Research output: Contribution to journal › Article › peer-review
Open Access263 Scopus citations -
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis
Carpenter, E. L., Van Decar, S., Adams, A. M., O'Shea, A. E., McCarthy, P., Chick, R. C., Clifton, G. T., Vreeland, T., Valdera, F. A., Tiwari, A., Hale, D., Kemp Bohan, P., Hickerson, A., Smolinsky, T., Thomas, K., Cindass, J., Hyngstrom, J., Berger, A. C., Jakub, J. & Sussman, J. J. & 5 others, , Aug 3 2023, In: Journal for ImmunoTherapy of Cancer. 11, 8, e006665.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations